Rah Jeong-Eun, Kim Gwe-Ya, Oh Do Hoon, Kim Tae Hyun, Kim Jong Won, Kim Dae Yong, Park Sung Yong, Shin Dongho
Department of Radiation Oncology, Myongji Hospital, Seonam University College of Medicine, Goyang, Korea.
Department of Radiation Medicine and Applied Sciences, University of California, San Diego, CA, USA.
Radiat Oncol. 2016 Oct 21;11(1):140. doi: 10.1186/s13014-016-0717-4.
The purpose of this study is to evaluate the dosimetric benefits of a proton arc technique for treating tumors of the para-aortic lymph nodes (PALN).
In nine patients, a proton arc therapy (PAT) technique was compared with intensity modulated radiation therapy (IMRT) and proton beam therapy (PBT) techniques with respect to the planning target volume (PTV) and organs at risk (OAR). PTV coverage, conformity index (CI), homogeneity index (HI) and OAR doses were compared. Organ-specific radiation induced cancer risks were estimated by applying organ equivalent dose (OED) and normal tissue complication probability (NTCP).
The PAT techniques showed better PTV coverage than IMRT and PBT plans. The CI obtained with PAT was 1.19 ± 0.02, which was significantly better than that for the IMRT techniques. The HI was lowest for the PAT plan and highest for IMRT. The dose to the OARs was always below the acceptable limits and comparable for all three techniques. OED results calculated based on a plateau dose-response model showed that the risk of secondary cancers in organs was much higher when IMRT or PBT were employed than when PAT was used. NTCPs of PAT to the stomach (0.29 %), small bowel (0.69 %) and liver (0.38 %) were substantially lower than those of IMRT and PBT.
This study demonstrates that there is a potential role for PAT as a commercialized instrument in the future to proton therapy.
本研究的目的是评估质子弧形技术治疗腹主动脉旁淋巴结(PALN)肿瘤的剂量学优势。
在9名患者中,将质子弧形治疗(PAT)技术与调强放射治疗(IMRT)和质子束治疗(PBT)技术在计划靶体积(PTV)和危及器官(OAR)方面进行比较。比较了PTV覆盖率、适形指数(CI)、均匀性指数(HI)和OAR剂量。通过应用器官等效剂量(OED)和正常组织并发症概率(NTCP)来估计器官特异性辐射诱发癌症的风险。
PAT技术显示出比IMRT和PBT计划更好的PTV覆盖率。PAT获得的CI为1.19±0.02,明显优于IMRT技术。PAT计划的HI最低,IMRT最高。OAR的剂量始终低于可接受限度,并且三种技术相当。基于平台剂量反应模型计算的OED结果表明,采用IMRT或PBT时器官中继发性癌症的风险远高于采用PAT时。PAT对胃(0.29%)、小肠(0.69%)和肝脏(0.38%)的NTCP明显低于IMRT和PBT。
本研究表明,PAT作为一种商业化仪器在未来质子治疗中具有潜在作用。